


Carcinomas of the Nasopharynx & Oropharynx Histopathology Reporting Proforma



Includes the  International Collaboration on Cancer reporting dataset denoted by *

Family name

Given name(s)

Date of birth

Patient identifiers

e.g. MRN, IHI or NHI (please indicate which)

Date of request

S1.03 Accession number

Requesting doctor - name and contact details

Sex

- Male
 Female
 Intersex/indeterminate

Ethnicity

- Unknown
 Aboriginal/Torres Strait Islander (AU)
 Māori (NZ)
 Other ethnicity:

Clinical information

S1.02 Not provided OR

*Neoadjuvant therapy

- Information not provided
 Not administered
 Administered, *specify type (select all that apply)*

- Chemotherapy
 Radiotherapy
 Targeted therapy, *specify if available*

Immunotherapy, *specify if available*

Time interval since therapy, *specify*

*Operative procedure (select all that apply)

- Resection, *specify*
 Transoral laser microsurgical resection
 Transoral robotic surgical resection
 Other, *specify*

Biopsy (excisional, incisional), *specify*

Neck (lymph node) dissection*, *specify*

Other, *specify*

* *If a neck dissection is submitted, then a separate protocol is used to record the information.*

*Specimen submitted (select all that apply)

- Oropharynx
 Palatine tonsil
 Base of tongue/lingual tonsil
 Soft palate
 Uvula
 Pharyngeal wall (posterior)
 Pharyngeal wall (lateral)
 Other, *specify*

Nasopharynx, *specify if necessary*

Other, *specify*

Anatomical site of lesion

Laterality of the lesion

- Left Right

Clinical history

Human papilloma virus (HPV) status

Clinical diagnosis or differential diagnosis

New primary lesion or recurrence

- New primary
 Recurrence - regional, *describe*
 Recurrence - distant, *describe*

G1.01 COPY TO DOCTORS

S1.04 PRINCIPAL CLINICIAN

G1.02 COMMENTS

Macroscopic findings

S2.01 SPECIMEN LABELLED AS

G2.01 SPECIMEN DIMENSIONS

Record for each specimen submitted

 x

G2.02 MUCOSAL SURFACE ABNORMALITIES/LESION(S)

- Not identified
 Present, *describe and measure*

S2.02 *TUMOUR SITE (select all that apply)

- Cannot be assessed
 Oropharynx
 Left Right
 Midline Laterality not specified

- Palatine tonsil
 Base of tongue/lingual tonsil
 Soft palate
 Uvula
 Pharyngeal wall (posterior)
 Pharyngeal wall (lateral)
 Other, *specify*

Nasopharynx

- Left Right
 Midline Laterality not specified

- Nasopharyngeal tonsils (adenoids)
 Fossa of Rosenmüller
 Lateral wall
 Other, *specify*

Other, *specify including laterality*

S2.03 * MAXIMUM DIMENSION OF LARGEST TUMOUR

- Cannot be assessed, *specify*

G2.03 ADDITIONAL DIMENSIONS OF LARGEST TUMOUR

 x

G2.04 TUMOUR DESCRIPTION (select all that apply)

- Exophytic Polypoid
 Endophytic Nodular
 Ulcerated

S2.04 MACROSCOPIC DEPTH OF INVASION

S2.05 SURGICAL MARGINS (specify margin)

AND mm

* Note that the margin and distance to lesion will need to be repeated for each surgical margin including the closest deep and circumferential margin.

S2.06 BLOCK IDENTIFICATION KEY

G2.05 ADDITIONAL MACROSCOPIC COMMENTS

Microscopic findings

S3.01 * HISTOLOGICAL TUMOUR TYPE

(Value list from the World Health Organization Classification of Head and Neck Tumours (2017))

Salivary gland carcinoma, specify type

Neuroendocrine carcinoma, specify type

Other, specify type

Carcinomas of the oropharynx

- Squamous cell carcinoma, conventional
 - Keratinizing Nonkeratinizing
 - Nonkeratinizing with maturation ("partially keratinizing")
- Acantholytic squamous cell carcinoma
- Adenosquamous carcinoma
- Basaloid squamous cell carcinoma
- Papillary squamous cell carcinoma
- Spindle cell carcinoma
- Verrucous carcinoma
- Lymphoepithelial carcinoma

Carcinomas of the nasopharynx

- Nonkeratinizing squamous cell carcinoma
 - Differentiated Undifferentiated (lymphoepithelial)
- Keratinizing squamous cell carcinoma
- Basaloid squamous cell carcinoma
- Nasopharyngeal papillary adenocarcinoma
- Cannot be assessed, specify

S3.02 * HISTOLOGICAL GRADE

- Not applicable
- GX: Cannot be assessed
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- Other, specify
- Cannot be assessed, specify

G3.01 * DEPTH OF INVASION

Not applicable
 Cannot be assessed, specify

S3.03 TUMOUR SIZE (greatest surface dimensions)

×

S3.04 TUMOUR SITE

- Base of tongue
- Tonsils
- Soft palate
- Posterior wall
- Ulvula
- Other, specify
- Cannot be assessed, specify

S3.05 * PERINEURAL INVASION

(Not applicable for nasopharynx)

- Not identified Present
- Cannot be assessed, specify

S3.06 * LYMPHOVASCULAR INVASION

(Not applicable for nasopharynx)

- Not identified Present
- Cannot be assessed, specify

S3.07 * MARGIN STATUS

Invasive carcinoma** (Only for large excision specimens)

Involved
Specify margin(s), if possible

Not involved
Distance of tumour from closest margin

 Distance not assessable
Specify closest margin, if possible

Carcinoma in situ/high-grade dysplasia***

Involved
Specify margin(s), if possible

Not involved
Distance of tumour from closest margin

 Distance not assessable
Specify closest margin, if possible

Not applicable ***

Cannot be assessed, *specify*

** *There is no clear morphologic distinction between invasive and in situ carcinoma for HPV-positive oropharyngeal and EBV-positive nasopharyngeal carcinomas, so all carcinoma at margin should be included in evaluation simply as "involved by carcinoma".*

*** *Only applicable for HPV-negative oropharyngeal and EBV-negative nasopharyngeal tumours and for tonsillar surface disease. High-grade dysplasia is synonymous with moderate/severe dysplasia.*

G3.02 * COEXISTENT PATHOLOGY (select all that apply)

None identified

Dysplasia^
 Mild
 Moderate
 Severe
 Focal Multifocal
 Discontinuous with the primary site

Carcinoma in situ
 Focal Multifocal
 Discontinuous with the primary site

Other, *specify*

^ *Applicable for oropharyngeal surface mucosal disease only; not for tonsillar crypt epithelium.*

G2.03 RADIATION INDUCED TISSUE DAMAGE

Not identified

Identified, *specify* (describe induced damage, if possible)

Cannot be assessed, *specify* (describe reason, if possible)

G3.04 ADDITIONAL MICROSCOPIC COMMENT

Ancillary findings

G4.01 * ANCILLARY STUDIES

Viral testing/Viral tumour markers

OROPHARYNX

Not performed/unknown

Performed (select all that apply)

p16 immunohistochemistry
 Positive
 >70% nuclear and cytoplasmic staining of at least moderate to strong intensity
 Other criterion used, *specify*

Negative
Criteria used to determine results, *specify*

High risk HPV specific testing

DNA PCR
 Not identified Present

DNA in situ hybridization
 Not identified Present

E6/E7 mRNA in situ hybridization
 Not identified Present

E6/E7 mRNA RTPCR
 Not identified Present

Viral testing/Viral tumour markers

NASOPHARYNX

Not performed/unknown

Performed
 EBV (EBER) in situ hybridization - Positive
 EBV (EBER) in situ hybridization - Negative

Other ancillary studies

Not performed

Performed, *specify*

Synthesis and overview

S5.01 *PATHOLOGICAL STAGING (AJCC TNM 8th edition)##

TNM Descriptors (only if applicable) (select all that apply)

- m - multiple primary tumours
- r - recurrent
- y - post-therapy

Primary tumour (pT)****

p16 Positive oropharynx

- T0 No primary identified
- T1 Tumour 2 cm or smaller in greatest dimension
- T2 Tumour larger than 2 cm but not larger than 4 cm in greatest dimension
- T3 Tumour larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis
- T4 Tumour invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond*

*Mucosal extension to lingual surface of epiglottis from primary tumours of the base of the tongue and vallecula does not constitute invasion of the larynx.

p16 Negative oropharynx

- TX Primary tumour cannot be assessed
- Tis Carcinoma *in situ*
- T1 Tumour 2 cm or smaller in greatest dimension
- T2 Tumour larger than 2 cm but not larger than 4 cm in greatest dimension
- T3 Tumour larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis

Nasopharynx

- TX Primary tumour cannot be assessed
- T0 No tumour identified, but EBV-positive cervical node(s) involvement
- T1 Tumour confined to nasopharynx, or extension to oropharynx and/or nasal cavity without parapharyngeal involvement
- T2 Tumour with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles)
- T3 Tumour with infiltration of bony structures at skull base, cervical vertebra, pterygoid structures, and/or paranasal sinuses
- T4 Tumour with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Eighth Edition (2016) published by Springer Science and Business Media LLC, www.springerlink.com

S5.02 Year of publication and edition of cancer staging system

G5.01 DIAGNOSTIC SUMMARY

Include: Specimen(s) submitted; Tumour type; Tumour grade; Tumour stage

S5.03 OVERARCHING COMMENT

G5.02 Edition/version number of the Structured Reporting Protocol.